{"id":56032,"date":"2026-02-02T17:08:58","date_gmt":"2026-02-02T09:08:58","guid":{"rendered":"https:\/\/flcube.com\/?p=56032"},"modified":"2026-02-02T17:08:59","modified_gmt":"2026-02-02T09:08:59","slug":"kyowa-kirin-reclaims-rocatinlimab-rights-from-amgen-in-strategic-shift","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56032","title":{"rendered":"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift"},"content":{"rendered":"\n

Kyowa Kirin<\/strong> (TYO: 4151<\/a>) announced it will cancel its licensing agreement<\/strong> with Amgen<\/strong> (NASDAQ:\u202fAMGN<\/a>) for rocatinlimab<\/strong>, an anti\u2011OX40 monoclonal antibody<\/strong>, regaining global rights<\/strong> to the asset. The drug, discovered in collaboration with the La Jolla Institute for Immunology<\/strong>, represents a core strategic priority for Kyowa Kirin\u2019s future pipeline.<\/p>\n\n\n\n

Deal Structure & Strategic Rationale<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Amgen (Nasdaq:\u202fAMGN)<\/td><\/tr>
Licensee (Returning)<\/strong><\/td>Kyowa Kirin (TSE:\u202f4151)<\/td><\/tr>
Drug<\/strong><\/td>Rocatinlimab (anti\u2011OX40 monoclonal antibody)<\/td><\/tr>
Action<\/strong><\/td>Licensing agreement cancellation<\/td><\/tr>
Rights Reversion<\/strong><\/td>Global rights return to Kyowa Kirin<\/td><\/tr>
Discovery Partner<\/strong><\/td>La Jolla Institute for Immunology<\/td><\/tr>
Strategic Priority<\/strong><\/td>Core asset for Kyowa Kirin\u2019s future pipeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Innovation<\/h2>\n\n\n\n
    \n
  • Mechanism:<\/strong> Anti\u2011OX40 monoclonal antibody<\/strong> designed for T\u2011cell rebalancing therapy<\/strong><\/li>\n\n\n\n
  • Unique Approach:<\/strong> Inhibits and reduces pathogenic effector and memory T cells<\/strong> by targeting the OX40 receptor<\/li>\n\n\n\n
  • Market Position:<\/strong> Potential first\u2011in\u2011class<\/strong> “T\u2011cell rebalancing” therapy<\/li>\n\n\n\n
  • Strategic Value:<\/strong> Represents cornerstone of Kyowa Kirin\u2019s clinical and commercial strategy in immunology<\/li>\n<\/ul>\n\n\n\n

    Market Impact & Commercial Outlook<\/h2>\n\n\n\n
      \n
    • Autoimmune Market:<\/strong> Global autoimmune market valued at $150\u202fbillion<\/strong> : in 2025; T\u2011cell targeted therapies gaining traction<\/li>\n\n\n\n
    • Competitive Landscape:<\/strong> Rocatinlimab would compete with JAK inhibitors<\/strong> and other biologics; OX40 mechanism offers differentiation<\/li>\n\n\n\n
    • Strategic Shift:<\/strong> Reclaiming global rights allows Kyowa Kirin to control development timeline, pricing, and commercial strategy<\/strong> in key markets<\/li>\n\n\n\n
    • Development Plans:<\/strong> Kyowa Kirin will leverage its clinical and commercial expertise to advance rocatinlimab independently<\/li>\n\n\n\n
    • Financial Impact:<\/strong> Transaction eliminates future milestone\/royalty obligations to Amgen, improving long\u2011term profitability<\/li>\n\n\n\n
    • Next Steps:<\/strong> Updated clinical development plan expected Q2\u202f2026<\/strong>; potential partnership discussions for ex\u2011Japan rights under evaluation<\/li>\n<\/ul>\n\n\n\n

      Forward\u2011Looking Statements<\/strong>
      This brief contains forward\u2011looking statements regarding development timelines, commercial strategy, and market potential for rocatinlimab. Actual results may differ due to clinical trial outcomes, competitive dynamics, and regulatory review processes.<\/p>\n","protected":false},"excerpt":{"rendered":"

      Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ:\u202fAMGN) for…<\/p>\n","protected":false},"author":1,"featured_media":56033,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[330,438,912,1212],"class_list":["post-56032","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-amgen","tag-kyowa-kirin","tag-nasdaq-amgn","tag-tyo-4151"],"yoast_head":"\nKyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ:\u202fAMGN) for rocatinlimab, an anti\u2011OX40 monoclonal antibody, regaining global rights to the asset. The drug, discovered in collaboration with the La Jolla Institute for Immunology, represents a core strategic priority for Kyowa Kirin\u2019s future pipeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56032\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift\" \/>\n<meta property=\"og:description\" content=\"Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ:\u202fAMGN) for rocatinlimab, an anti\u2011OX40 monoclonal antibody, regaining global rights to the asset. The drug, discovered in collaboration with the La Jolla Institute for Immunology, represents a core strategic priority for Kyowa Kirin\u2019s future pipeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56032\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T09:08:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-02T09:08:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56032#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56032\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift\",\"datePublished\":\"2026-02-02T09:08:58+00:00\",\"dateModified\":\"2026-02-02T09:08:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56032\"},\"wordCount\":300,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56032#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0203.webp\",\"keywords\":[\"Amgen\",\"Kyowa Kirin\",\"NASDAQ: AMGN\",\"TYO: 4151\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56032#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56032\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56032\",\"name\":\"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56032#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56032#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0203.webp\",\"datePublished\":\"2026-02-02T09:08:58+00:00\",\"dateModified\":\"2026-02-02T09:08:59+00:00\",\"description\":\"Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ:\u202fAMGN) for rocatinlimab, an anti\u2011OX40 monoclonal antibody, regaining global rights to the asset. The drug, discovered in collaboration with the La Jolla Institute for Immunology, represents a core strategic priority for Kyowa Kirin\u2019s future pipeline.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56032#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56032\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56032#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0203.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56032#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift - Insight, China's Pharmaceutical Industry","description":"Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ:\u202fAMGN) for rocatinlimab, an anti\u2011OX40 monoclonal antibody, regaining global rights to the asset. The drug, discovered in collaboration with the La Jolla Institute for Immunology, represents a core strategic priority for Kyowa Kirin\u2019s future pipeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56032","og_locale":"en_US","og_type":"article","og_title":"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift","og_description":"Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ:\u202fAMGN) for rocatinlimab, an anti\u2011OX40 monoclonal antibody, regaining global rights to the asset. The drug, discovered in collaboration with the La Jolla Institute for Immunology, represents a core strategic priority for Kyowa Kirin\u2019s future pipeline.","og_url":"https:\/\/flcube.com\/?p=56032","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-02T09:08:58+00:00","article_modified_time":"2026-02-02T09:08:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56032#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56032"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift","datePublished":"2026-02-02T09:08:58+00:00","dateModified":"2026-02-02T09:08:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56032"},"wordCount":300,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56032#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0203.webp","keywords":["Amgen","Kyowa Kirin","NASDAQ: AMGN","TYO: 4151"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56032#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56032","url":"https:\/\/flcube.com\/?p=56032","name":"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56032#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56032#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0203.webp","datePublished":"2026-02-02T09:08:58+00:00","dateModified":"2026-02-02T09:08:59+00:00","description":"Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ:\u202fAMGN) for rocatinlimab, an anti\u2011OX40 monoclonal antibody, regaining global rights to the asset. The drug, discovered in collaboration with the La Jolla Institute for Immunology, represents a core strategic priority for Kyowa Kirin\u2019s future pipeline.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56032#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56032"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56032#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0203.webp","width":1080,"height":608,"caption":"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56032#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56032"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56032\/revisions"}],"predecessor-version":[{"id":56034,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56032\/revisions\/56034"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56033"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}